Literature DB >> 30875063

Evidence mapping based on systematic reviews of therapeutic interventions for soft tissue sarcomas.

M Ballesteros1, N Montero2, A López-Pousa3, G Urrútia4,5, I Solà4,5, G Rada6, H Pardo-Hernandez4,5, X Bonfill4,5.   

Abstract

PURPOSE: Soft tissue sarcomas are a heterogeneous group of rare tumours of mesenchymal origin. Evidence mapping is one of the most didactic and friendly approaches to organise and summarise the range of research activity in broad topic fields. The objective of this evidence mapping is to identify, describe and organise the current available evidence about therapeutic interventions on soft tissues sarcomas.
METHODS: We followed the methodology of global evidence mapping. We performed a search of the PubMed, EMBASE, The Cochrane Library and Epistemonikos to identify systematic reviews (SRs) with or without meta-analyses published between 1990 and March 2016. Two independent literature reviewers assessed eligibility and extracted data. Methodological quality of the included systematic reviews was assessed using AMSTAR. We organised the results according to identified PICO questions and used tables and a bubble plot to display the results.
RESULTS: The map is based on 24 SRs that met eligibility criteria and included 66 individual studies. Three-quarters were either observational or uncontrolled clinical trials. The quality of the included SRs was in general moderate or high. We identified 64 PICO questions from them. The corresponding results mostly favoured the intervention arm.
CONCLUSIONS: This evidence mapping was built on the basis of SRs, which mostly included non-experimental studies and were qualified by the AMSTAR tool as of moderate quality. The evidence mapping created from PICO questions is a useful approach to describe complex and huge clinical topics through graphical media and orientate further research to fulfil the existing gaps. However, it is important to delimitate the steps of the evidence mapping in a pre-established protocol.

Entities:  

Keywords:  Evidence mapping; Evidence synthesis; Global evidence mapping; Soft tissue sarcomas

Mesh:

Year:  2019        PMID: 30875063     DOI: 10.1007/s12094-019-02069-z

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  43 in total

1.  A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma.

Authors:  Nabeel Pervaiz; Nigel Colterjohn; Forough Farrokhyar; Richard Tozer; Alvaro Figueredo; Michelle Ghert
Journal:  Cancer       Date:  2008-08-01       Impact factor: 6.860

2.  Effective stakeholder participation in setting research priorities using a Global Evidence Mapping approach.

Authors:  Ornella Clavisi; Peter Bragge; Emma Tavender; Tari Turner; Russell L Gruen
Journal:  J Clin Epidemiol       Date:  2012-07-18       Impact factor: 6.437

3.  Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors: 
Journal:  Ann Oncol       Date:  2014-09       Impact factor: 32.976

Review 4.  Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients.

Authors:  Renée L Mulder; Marios Paulides; Thorsten Langer; Leontien C M Kremer; Elvira C van Dalen
Journal:  Cochrane Database Syst Rev       Date:  2015-09-30

5.  Soft tissue sarcoma, version 2.2014.

Authors:  Margaret von Mehren; R Lor Randall; Robert S Benjamin; Sarah Boles; Marilyn M Bui; Ephraim S Casper; Ernest U Conrad; Thomas F Delaney; Kristen N Ganjoo; Suzanne George; Ricardo J Gonzalez; Martin J Heslin; John M Kane; Joel Mayerson; Sean V McGarry; Christian Meyer; Richard J O'Donnell; Alberto S Pappo; I Benjamin Paz; John D Pfeifer; Richard F Riedel; Scott Schuetze; Karen D Schupak; Herbert S Schwartz; Brian A Van Tine; Jeffrey D Wayne; Mary Anne Bergman; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2014-04       Impact factor: 11.908

6.  Isolated limb perfusion: what is the evidence for its use?

Authors:  Eva M Noorda; Bart C Vrouenraets; Omgo E Nieweg; Frits Van Coevorden; Bin B R Kroon
Journal:  Ann Surg Oncol       Date:  2004-08-16       Impact factor: 5.344

7.  The Global Evidence Mapping Initiative: scoping research in broad topic areas.

Authors:  Peter Bragge; Ornella Clavisi; Tari Turner; Emma Tavender; Alex Collie; Russell L Gruen
Journal:  BMC Med Res Methodol       Date:  2011-06-17       Impact factor: 4.615

8.  Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing.

Authors:  Françoise Ducimetière; Antoine Lurkin; Dominique Ranchère-Vince; Anne-Valérie Decouvelaere; Michel Péoc'h; Luc Istier; Philippe Chalabreysse; Christine Muller; Laurent Alberti; Pierre-Paul Bringuier; Jean-Yves Scoazec; Anne-Marie Schott; Christophe Bergeron; Dominic Cellier; Jean-Yves Blay; Isabelle Ray-Coquard
Journal:  PLoS One       Date:  2011-08-03       Impact factor: 3.240

9.  Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews.

Authors:  Beverley J Shea; Jeremy M Grimshaw; George A Wells; Maarten Boers; Neil Andersson; Candyce Hamel; Ashley C Porter; Peter Tugwell; David Moher; Lex M Bouter
Journal:  BMC Med Res Methodol       Date:  2007-02-15       Impact factor: 4.615

10.  Evidence mapping based on systematic reviews of therapeutic interventions for gastrointestinal stromal tumors (GIST).

Authors:  Mónica Ballesteros; Nadia Montero; Antonio López-Pousa; Gerard Urrútia; Ivan Solà; Gabriel Rada; Hector Pardo-Hernandez; Xavier Bonfill
Journal:  BMC Med Res Methodol       Date:  2017-09-07       Impact factor: 4.615

View more
  1 in total

Review 1.  Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews.

Authors:  Nadia Montero-Oleas; Ingrid Arevalo-Rodriguez; Solange Nuñez-González; Andrés Viteri-García; Daniel Simancas-Racines
Journal:  BMC Complement Med Ther       Date:  2020-01-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.